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Abstract
Background: Recent studies indicate that microRNAs (miRNAs) are mechanistically involved in the
development of various human malignancies, suggesting that they represent a promising new class of
cancer biomarkers. However, previously reported methods for measuring miRNA expression consume
large amounts of tissue, prohibiting high-throughput miRNA profiling from typically small clinical samples
s u c h  a s  e x c i s i o n  o r  c o r e  n e e d l e  b i o p s i e s  o f  b r e a st or prostate cancer. Here we describe a novel
combination of linear amplification and labeling of miRNA for highly sensitive expression microarray
profiling requiring only picogram quantities of purified microRNA.
Results: Comparison of microarray and qRT-PCR measured miRNA levels from two different prostate
cancer cell lines showed concordance between the two platforms (Pearson correlation R2 = 0.81); and
extension of the amplification, labeling and microarray platform was successfully demonstrated using
clinical core and excision biopsy samples from breast and prostate cancer patients. Unsupervised
clustering analysis of the prostate biopsy microarrays separated advanced and metastatic prostate cancers
from pooled normal prostatic samples and from a non-malignant precursor lesion. Unsupervised clustering
of the breast cancer microarrays significantly distinguished ErbB2-positive/ER-negative, ErbB2-positive/ER-
positive, and ErbB2-negative/ER-positive breast cancer phenotypes (Fisher exact test, p = 0.03); as well,
supervised analysis of these microarray profiles identified distinct miRNA subsets distinguishing ErbB2-
positive from ErbB2-negative and ER-positive from ER-negative breast cancers, independent of other
clinically important parameters (patient age; tumor size, node status and proliferation index).
Conclusion: In sum, these findings demonstrate that optimized high-throughput microRNA expression
profiling offers novel biomarker identification from typically small clinical samples such as breast and
prostate cancer biopsies.
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Background
MicroRNAs (miRNA) are a class of small non-coding
RNAs encoded in the genomes of animals and plants [1-
4] that play a role in targeting messages of protein-coding
genes for cleavage or translational repression [5,6]. The
active miRNA products ~22 nt in length are formed from
larger 60–110 nt hairpin precursor transcripts that serve as
substrates for the dsRNA endoribonuclease Dicer [7,8].
The mature miRNAs formed by Dicer cleavage are short
dsRNA molecules, one strand of which is incorporated
into the ribonucleoprotein complex RISC (RNA induced
silencing complex) for subsequent targeting to mRNAs
[9]. Complementary mRNA sequences are inactivated by
cleavage in a fashion similar to RNAi, while pairing with
partially complementary sequences in the 3' UTR of target
mRNAs can either repress translational efficiency or
induce transcript decay [10-12]. Present estimates suggest
that nearly a third of all cellular transcripts may be regu-
lated by the few hundred human miRNAs currently
known to exist [1].
Recently, miRNAs have been shown capable of distin-
guishing the different tissue developmental lineages and
differentiation states of various human malignancies [13],
including breast cancer [14]. In particular, comparison of
normal and malignant breast tissue has revealed that a
small subset of deregulated miRNAs (including mir-125b,
mir-145, mir-21, and mir-155) can be identified that une-
quivocally distinguish normal from malignant breast tis-
sue, as well as other differentially expressed miRNAs that
appear to correlate with breast cancer histopathologic fea-
tures such as tumor size, nodal involvement, proliferative
capacity and vascular invasiveness [14]. While specific
miRNAs may be postulated to regulate the expression of
genes involved in receptor networks known to drive breast
cancer progression, miRNA profiling has not yet been
shown capable of independently identifying breast cancer
phenotypes clinically defined by the overexpression of
ErbB2 and/or estrogen receptor (ER) proteins. Nonethe-
less, the provocative early observations of miRNAs
expressed in human breast cancer are stimulating broad
interest in the possibility that miRNA profiles represent a
promising new class of cancer biomarkers. However,
progress in more widespread evaluation of miRNAs as
potential cancer biomarkers remains limited by current
miRNA assay methods and platforms.
The most extensively used approaches to miRNA identifi-
cation and quantification include cloning, northern blot,
and microarray-based methods. Cloning methods can
require hundreds of micrograms of total RNA [15-17],
while northern blot methods typically use 10–30 µg per
analysis [10,16,17]. These methods are problematic in
that they are not high-throughput and they consume far
more tissue-derived RNA than is typically available from a
clinical biopsy sample. Several previously described high-
throughput microarray approaches, as well as other plat-
forms, also utilize microgram or greater quantities of total
RNA [13,18-23]. Depending on the number of core biop-
sies taken per patient, as well as the number and thickness
of tissue sections made available, total sample yield from
a typical core biopsy may be 200 ng or less of total RNA.
Thus, in order to perform high-throughput microarray-
based miRNA expression profiling on typical clinical
biopsy samples, further optimization of miRNA analysis
is needed. We adapted a previously described method
[24] for the amplification and labeling of miRNAs for
microarray-based analysis and compared expression lev-
els to levels detected by a TaqMan® quantitative RT-PCR
platform. Our high-throughput miRNA expression profil-
ing approach was ultimately applied to test the ability of
differentially expressed miRNAs to distinguish malignant
from non-malignant prostate cancer samples, and to
blindly classify breast cancers in accordance with their
clinically defined ErbB2 and ER status as well as poten-
tially identify miRNA signatures associated with ErbB2
and ER phenotypes.
Results
Reproducibility of miRNA profiling by microarrays and 
their validation by qRT-PCR
To examine the reproducibility of the labeling procedure
(Additional file 1) equal amounts of miRNA (150 ng,
derived from about 1.0 microgram of totalRNA) from the
human prostate cell line PC3 was labeled with Cy3 and
Cy5 in parallel reactions and hybridized to sense strand-
spotted arrays. A comparison of the Cy3 and Cy5 labeled
PC3 miRNA signal intensities indicated highly reproduci-
ble labeling of the same sample in both channels (R2 =
0.99, Additional file 2). In further examination of repro-
ducibility, duplicate labeling reactions were performed
using 100 ng of normal (Cy3) and tumor (Cy5) miRNA
samples for hybridization to the arrays. Comparison of
the Cy3/Cy5 ratios between the two representative arrays
showed a high degree of concordance (R2 = 0.94, Addi-
tional file 2). Multiple replicates of labeled PC3 vs. LNCaP
miRNA revealed distinct expression patterns between the
two cancer cell lines that were highly consistent; Figure 1
displays the averages of the duplicate spots for each
miRNA probe. Due to the high concordance between rep-
licate spots, averaging of the duplicates had little to no
effect on the microarray analysis results. Successful labe-
ling and expression profiling was achieved with as little as
10 ng of enriched miRNA.
Microarray analyses identified differentially expressed
miRNAs when comparing the expression patterns of the
hormone sensitive LNCaP and hormone insensitive PC3
prostate cancer cell lines. To verify the accuracy of these
microarray results we measured expression of individualMolecular Cancer 2006, 5:24 http://www.molecular-cancer.com/content/5/1/24
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Comparison of microRNA expression in PC3 and LNCaP cells by microarray analysis Figure 1
Comparison of microRNA expression in PC3 and LNCaP cells by microarray analysis. A heat map of replicate 
experiments (N = 6) that displays the relative Cy3/Cy5 ratios of microRNAs expressed in PC3(Cy3) vs.LNCaP(Cy5) cells. 
Expression levels on individual arrays were calculated by averaging the duplicate spots for each miRNA. MicroRNAs are listed 
in order of significance as determined by SAM analysis. MicroRNA expression is displayed as higher (red) or lower (green) in 
LNCaP cells in comparison to PC3 cells.
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miRNAs by a real-time quantitative TaqMan qRT-PCR
method designed to detect mature miRNA sequences [25].
Figure 2 displays a comparison of qRT-PCR and microar-
ray results for those microRNAs differentially expressed
between LNCaP and PC3 cells. Analysis of the fold
changes for these miRNAs showed good concordance (R2
~ 0.81) between the microarray and RT-PCR platforms.
We did not observe any cases where the direction of the
change in miRNA expression was discordant between the
two platforms; the only discordance observed was for let-
Comparison of microRNA expression measurements by microarray and RT-PCR Figure 2
Comparison of microRNA expression measurements by microarray and RT-PCR. A) A heat map comparing the 
average fold-changes in microRNAs with significantly higher (red) or lower (green) expression in LNCaP cells in comparison to 
PC3 cells as determined either by Taqman® qRT-PCR or microarray analysis (unamplified and amplified). Genes included in the 
figure are those found to be significantly different by one or both methods. Mir-130b and miR-301 were not found to be signif-
icantly different in amplified samples by SAM analysis. B) Pearson correlation scatter plots of comparisons of array data to 
qRT-PCR for amplified and unamplified miRNA.
Unamplified Amplified qRT-PCR
miR99a
miR200c
miR148a
miR34a
let7b
miR106b
miR26a
miR15a
let7a
miR195
miR148b
miR28
let7e
miR25
miR93
miR181a
miR23b
miR27b
miR21
miR130b
miR301
miR29a
miR99b
miR320
miR24
miR27a
miR125a
miR23a
miR151
miR183
miR221
miR222
miR10a
miR22
miR210
miR100
miR30a5p
miR107
miR342
miR191
miR103
miR15b
miR92
miR30d
miR30c
miR30a3p
Unamplified vs. qRT-PCR
R
2
= 0.8082
-8
-6
-4
-2
0
2
4
6
-6 -4 -2 0 2 4 6
Amplified vs. qRT-PCR
R
2
= 0.8133
-8
-6
-4
-2
0
2
4
6
8
-8 -6 -4 -2 0 2 4 6
A B
log median
ratio:
-3
-2
-1.5
-1
-0.5
0.5
1
1.5
2
3
>3Molecular Cancer 2006, 5:24 http://www.molecular-cancer.com/content/5/1/24
Page 5 of 14
(page number not for citation purposes)
7 miRNA family members which were found upregulated
by microarray measurement and not significantly
changed by qRT-PCR measurement (Additional file 3).
Sensitivity and reproducibility of the miRNA amplification 
procedure
The linear amplification technique developed for miRNA
expression profiling in cases where starting sample
amount is very limited is schematically shown in Figure 3,
and represents an adaptation of a previously reported
method[24]. Five different input amounts of miRNA were
titrated into the amplification protocol to determine line-
arity of the yield; as shown in Table 1 the yields from this
titration produced an excellent linear regression correla-
tion (R2 = 0.95). Amplification of miRNA by this method
has been successfully performed on as little as 250 pg of
enriched miRNA (~2 ng total RNA), an amount of RNA
easily obtained from needlecore biopsies or even fine nee-
dle aspirates.
To examine the reproducibility of the amplification proce-
dure, 500 pg of enriched miRNA isolated from a prostate
needle core biopsy was amplified in duplicate. Equal
amounts (750 ng) of both amplifications were labeled
with either Cy3 or Cy5 and hybridized to an array. Com-
parison of the respective signal intensities showed highly
reproducible amplification and labeling (R2 = 0.988, Sup-
plemental file 2). Additionally, the fidelity of the amplifi-
cation procedure was assessed by comparing microarrays
of unamplified and amplified miRNA samples derived
from tumor and normal (adjacent to tumor) tissue from
the same patient. For the amplified samples, 500 pg of
enriched tumor and normal miRNA was amplified, and 1
µg from each reaction was labeled with either Cy3
(tumor) or Cy5 (normal). Parallel labeling reactions were
performed using 150 ng of unamplified miRNA from the
same samples. Comparison of the differential expression
of amplified to unamplified miRNAs showed that the
amplification procedure produced excellent fidelity in
miRNA representation (R2 = 0.875). As well, microarray
comparison of amplified PC3 and LNCaP miRNAs pro-
duced a similar degree of concordance with unamplified
samples (R2 = 0.8133), and also with qRT-PCR measure-
ments (R2 = 0.8082), as shown in Figure 3.
MicroRNA expression profiling distinguishes malignant 
from non-malignant prostate tissue
Microarray profiling of miRNAs isolated and amplified
from prostate needle core biopsy specimens was per-
formed to demonstrate the utility of this methodology on
small clinical samples. Pooled normal prostate miRNA
was made from total RNA individually extracted from 10
different needle core prostate biopsies showing normal
histology (average patient age, 63 years). A total of 20 ng
pooled total RNA from the 10 biopsies was enriched for
miRNA (as described in Methods) and amplified. The
pooled and amplified normal prostate miRNA was com-
pared against enriched and amplified miRNA samples (10
ng) produced from two abnormal prostate needle core
biopsies (one showing an advanced prostate cancer and
another showing a non-malignant precursor lesion
referred to as transitional cell metaplasia), and a fine nee-
dle aspirate of a prostate cancer metastasis to a supracla-
vicular lymph node. As shown in Figure 4, unsupervised
clustering analysis performed on the different microar-
rayed miRNA samples (pooled normal prostate, two nee-
dle core cancer biopsies, fine needle node aspirate, and
PC3 and LNCaP reference samples) unequivocally dis-
criminated the prostatic cancer tissues from the pooled
normal samples and non-malignant precursor lesion.
MicroRNA expression profiling identifies clinically relevant 
breast cancer phenotypes
Overexpression of either the ErbB2 or ER receptors usually
results in clinically distinct breast cancer phenotypes,
which are detectable by gene expression profiling [26].
However, breast cancer overexpression of both ErbB2 and
ER is not uncommon and is associated with a different
and clinically troublesome phenotype [27]. A panel of 20
different breast cancer samples was chosen to represent
these three common phenotypes (9/20, ErbB2-positive/
ER-negative; 4/20, ErbB2-positive/ER-positive; 7/20,
ErbB2-negative/ER-positive) and was blindly analyzed for
miRNA expression levels by microarray profiling. Since a
sample of pooled normal mammary gland total RNA was
not available, all tumor miRNA samples were normalized
to miRNA prepared from a single age-matched sample of
normal mammary gland tissue. An ErbB2-positive/ER-
negative breast cancer cell line, SKBr3, was also used for
reference. Comparable with regard to histology and stage,
the cancers had also previously been annotated with
regard to progesterone receptor (PR) overexpression (11/
20), tumor cell proliferation index, and the presence of
any p53 DNA mutations (see Additional file 4 for clinical
annotation). Using 500 ng of total RNA from all samples,
10 ng of miRNA was amplified and the resulting amplifi-
cation product labeled and array hybridized.
As shown in Figure 5, unsupervised hierarchical clustering
of the resulting miRNA profiles revealed 2 or 3 major den-
Table 1: Titration of amplified miRNA
miRNA input (ng) Yield (ng)
0.5 2664
12 7 9 1
38 1 6 5
92 2 7 3 6
27 40340Molecular Cancer 2006, 5:24 http://www.molecular-cancer.com/content/5/1/24
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Schematic of microRNA amplification procedure Figure 3
Schematic of microRNA amplification procedure. A poly A tail is first added at the 3' end of microRNAs. Reverse tran-
scription performed using a primer consisting of an oligo dT and a capture sequence. Next, the first strand cDNA is tailed with 
dTTP using terminal deoxynucleotidyl transferase on the 5' end, followed by annealing of a T7 template oligo to the 3' tail of 
the cDNA. Klenow enzyme fills in the 3' end of the first strand cDNA to produce a double-stranded T7 promoter. The T7 
template contains a blocker to prevent second strand synthesis. An in vitro transcription reaction with T7 RNA polymerase is 
then performed. Amplified products are then labeled using the method previously mentioned starting at the reverse transcrip-
tion step.
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Unsupervised hierarchical cluster of amplified prostate needle core biopsies Figure 4
Unsupervised hierarchical cluster of amplified prostate needle core biopsies. Expression patterns of amplified 
miRNA from a small set of clinical prostate specimens. Cluster analysis of the microarrays displayed shows a cluster on the left 
consisting of an advanced needle core biopsy of an advanced prostatic tumor (Gleason score 8) and a fine needle aspirate of a 
prostatic lymph node metastasis (FNA), a cluster in the middle consisting of PC3 and LNCaP prostate tumor cell lines, and a 
cluster on the right consisting of a pooled normal adjacent to tumor sample and another sample consisting of transitional cell 
metaplasia (TCM), an early precursor lesion.
T
u
m
o
r
G
S
8
F
N
A
P
C
3
L
N
C
A
P
P
o
o
l
e
d
n
o
r
m
a
l
T
C
M
miR205*
miR148a*
miR148b*
miR148a
miR15a*
miR30c
miR19b*
miR19b
miR19a*
miR19a
miR3243p
miR149*
miR200a*
miR200a
miR150
miR29b*
miR29b
miR152
miR127
miR152*
miR127*
miR199b
miR126*
miR199a*
miR199a**
miR126
miR126*
miR145*
miR145
miR143*
miR143
miR199a
miR199b*
miR30c*
miR27b*
miR27b
miR199a*
miR130a
miR150*
miR101
miR148b
let7d
miR98
let7d*
miR183
miR98*
miR182*
miR128a*
miR128b
miR345
miR151
miR331*
miR99b*
miR99b
miR200b
miR106a*Molecular Cancer 2006, 5:24 http://www.molecular-cancer.com/content/5/1/24
Page 8 of 14
(page number not for citation purposes)
Unsupervised hierarchical cluster of breast tumor samples Figure 5
Unsupervised hierarchical cluster of breast tumor samples. The tree was generated by cluster analysis of all 20 breast 
tumor tissue samples and displays the clinical pathologic features for ErbB2, estrogen receptor (ER), progesterone receptor 
(PR), and p53 (w = wild type, m = mutant). Cluster analysis revealed three distinct branches of the dendrogram. Duplicate 
spots for each probe are displayed and were not averaged for this analysis to demonstrate the consistency of expression values 
between duplicate spots. The probe sequence for mir-126* is distinctively different from mir-126.
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drogram groups. Unblinding this analysis to the clinical
annotation of each sample revealed that the 2 mostprom-
inent dendrogram groups were primarily distinguished by
lack of ER-positive (2/7) or PR-positive cancers (2/7) in
the first group and the presence of ER-positive (9/13) or
PR-positive cancers (8/13) in the second group; these dif-
ferences did not quite achieve statistical significance
(Fisher Exact test, p = 0.16). In contrast, the 3 major den-
drogram arms were primarily distinguished by their differ-
ent proportions of ErbB2-positive cancers, with the first
showing almost exclusively ErbB2-positive cancers (6/7),
the second showing very few ErbB2-positive cancers (3/9),
and the smallest and most heterogeneous of these arms
showing only ErbB2-positive cancers (4/4). These ErbB2
differences between the 3 major dendrogram arms proved
statistically significant (Fisher's Exact test, p = 0.03); and
in consideration with ER status these 3 groups suggest that
they may be generally representative of ErbB2-positive/
ER-negative, ErbB2-negative/ER-positive, and ErbB2-posi-
tive/ER-positive breast cancers, respectively. When the
miRNA levels detected in the ErbB2-positive breast can-
cers were averaged apart from the other breast cancers and
compared to the 67 different miRNAs found expressed in
the ErbB2-positive breast cancer cell line, SKBr3, a surpris-
ing concordance was observed (Spearman rank order cor-
relation, Rs = +0.43, n = 67, p < 0.001), suggesting that this
cell line model of ErbB2-positive breast cancer closely
reflects the miRNA expression profile found in clinical
samples of ErbB2-positive breast cancers (Supplement file
4). No significant differences were found between any of
the three breast cancer subgroups (Fisher's Exact test, p >
0.10) when evaluated by any of other clinically relevant
parameters (patient age,% tumor cells, tumor size, nodal
status, grade, proliferation index, p53 status; Additional
file 5).
SAM analyses were performed on the entire set of 20
breast cancers to identify potential differences in miRNA
signatures between the following phenotypic groups:
ErbB2-negative vs. ErbB2-positive, ER-positive vs. ER- neg-
ative, PR-positive vs. PR-negative, and mutated vs. wild
type p53. No significant differences were found according
to p53 status, although this analysis was obviously limited
by the few cases containing mutated p53. For ErbB2 sta-
tus, however, it was found that 43 miRNAs were signifi-
cantly higher in ErbB2-negative as compared to ErbB2-
positive breast cancers. Likewise, 43 miRNAs were signifi-
cantly higher in ER-positive vs. ER-negative cancers, while
46 miRNAs were higher in PR-positive vs. PR-negative
cancers. Comparison of the three signature profiles asso-
ciating with ErbB2, ER and PR status (Figure 6) revealed
many genes in common and a more restricted subset of
miRNAs specific to ErbB2 status (let-7f, let-7g, miR-107,
mir-10b, miR-126, miR-154 and miR-195) and a smaller
Comparison of miRNA expression profiles associated with  receptor status Figure 6
Comparison of miRNA expression profiles associated 
with receptor status. A) Heat map of genes found signifi-
cantly different according to SAM analysis. Map displays 
genes significantly higher in ErbB2-negative vs. ErbB2-positive 
tumors, genes significantly higher in ER-positive vs. ER-nega-
tive tumors and genes significantly higher in PR-positive vs. 
PR-negative tumors.
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subset specific to ER/PR status (miR-142-5p, miR-200a,
miR-205 and miR-25).
Discussion
The amplification, labeling and microarray methodology
described herein permits sensitive, accurate, and high-
throughput microRNA profiling of small clinical sample
specimens. Faithful amplification was achieved using as
little as 250 pg of enriched miRNA (~2 ng total RNA), an
amount easily obtainable from needle core biopsies or
even fine needle aspirates. The amplified miRNA demon-
strated good replication fidelity in comparison to unam-
plified RNA, indicating that all species of miRNAs were
comparably amplified and suggesting that this procedure
is superior to alternative methods such as blunt-end liga-
tion of adaptors for PCR amplification, which suffer from
questionable RNA ligase reliability. Use of a dendrimer-
based labeling system [28] in combination with miRNA
amplification is key to achieving high miRNA detection
sensitivity. The dendrimer approach has an advantage
over direct and other indirect labeling methods because
the multiple fluorophores are an integral part of the den-
drimer and do not have to be incorporated during cDNA
preparation; this avoids inefficient hybridization of the
cDNA to the array by incorporation of fluorescent dye
conjugates into the reverse transcript [29]. Since each
branched dendrimer has approximately 900 attached
fluorophores, miRNA signal intensity is amplified and
10–20 fold less input miRNA is required as compared to
other previously reported techniques [28,30,31].
Results using this amplification and labeling methodol-
ogy in conjunction with the microarray platform were val-
idated by comparison with Q-RT-PCR measurement of
miRNA levels. Only the levels of selected let-7 family
members showed differences between microarray and RT-
PCR quantitation. Since different let-7 family members
may differ in sequence by only one nucleotide, there is
some question regarding how accurately probes can dis-
tinguish such similar family members. In our previous
experiments let-7 amicroarray levels were in agreement
with northern blot results [32]; as well, microarray results
for other miRNAs showing very similar sequences did not
appear discordant with qRT-PCR results. Of note, the qRT-
PCR method used here (Applied Biosystems) discrimi-
nates between single-base pair differences using gene-spe-
cific hairpin primers for the initial reverse transcription
reaction. Additional specificity is achieved with the type of
primers used in the qRT-PCR reaction. Using hairpin
primers, the qRT-PCR method only detects mature miR-
NAs. Thus, we cannot rule out the possibility that imma-
ture forms of miRNA also hybridized to the probes on the
microarrays, thereby inflating expression levels relative to
those measured by qRT-PCR. However, based on our pre-
vious studies and those of others [32,33], the relative lev-
els of precursor miRNAs are very low in comparison to
mature miRNA forms. We acknowledge that normaliza-
tion of qRT-PCR data by any particular miRNA(s) can
skew the results in either direction. In the absence of any
current consensus in the field regarding appropriate
"housekeeping gene equivalents" in miRNA enriched frac-
tions, we have since moved toward other statistical
approaches such as scale factor normalization. Regardless
of the normalization approach for the qRT-PCR data,
there would not be a large impact on the correlation of
expression values between microarray and qRT-PCR plat-
forms. Northern blot confirmations in our subsequent
studies [32] have also been consistent with our microarray
results, giving confidence about results we report here,
with the limitations of let-7 family member measure-
ments due to the design of the array platform at the time
these studies were conducted. Developing high-through-
put microarray platforms that achieve highly sensitive and
accurate discrimination of all miRNAs, including the most
homologous of paralogs, remains a technical challenge,
although recent studies suggest that further microarray
detection specificity may be achieved by employing
locked nucleic acid (LNA) modified oligonucleotides
[21,34,35]. Improvements to the TaqMan miRNA assays
and microarray platforms that have been made since the
experiments described here are likely to further improve
concordance between the detection platforms.
Microarray analysis of prostate biopsy samples and a
panel of breast cancer samples served to validate the feasi-
bility and utility of this new high-throughput methodol-
ogy of miRNA profiling, proving it to be sufficiently
sensitive and accurate for routine use on small clinical
specimens such as those typically obtained by core biop-
sies or even fine needle aspiration. The informative nature
and potential biomarker utility of the miRNA profiles
detected in these clinical samples was revealed by unsu-
pervised clustering analysis blinded to the samples' clini-
cal annotations. The prostate biopsy miRNA profiles
clearly discriminated between the malignant and non-
malignant samples, while the breast cancer miRNA pro-
files discriminated clinically relevant breast cancer pheno-
types.
The panel of 20 breast cancer samples was chosen a priori
to represent three clinically important breast cancer sub-
types, defined by ErbB2 and ER receptor status. Modern
breast cancer treatments are based on these two validated
biomarkers since ErbB2-positive breast cancers are treated
with the ErbB2-targeted antibody, trastuzumab (Hercep-
tin©), while ER-positive breast cancers are treated with
either antiestrogens or estrogen-ablating aromatase inhib-
itors. At least a third of all ErbB2-positive breast cancers
are also ER-positive, and because this breast cancer sub-
group appears more refractory to all forms of endocrineMolecular Cancer 2006, 5:24 http://www.molecular-cancer.com/content/5/1/24
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therapy [27], it has attracted considerable attention
among basic and clinical breast cancer investigators.
ErbB2-positive and ER-positive breast cancers have been
shown to exhibit significantly different gene expression
profiles[26], however, gene expression studies to date
have failed to discriminate ErbB2-positive/ER-positive
breast cancers from either ErbB2-positive or ER-positive
subgroups. It is therefore of great interest that unsuper-
vised clustering of the miRNA profiles from the 20 breast
cancer samples studied here clearly discriminated at least
two subsets of ErbB2-positive breast cancers, one that is
largely ErbB2-positive and ER-negative, and another more
remotely related group of ErbB2-positive cancers with
miRNA features more typical of ER-positive breast can-
cers. Additional breast cancer samples must be studied to
conclusively identify a profile of miRNAs that define this
clinically important subset of ErbB2-positive/ER-positive
breast cancers. The important possibility that microRNA
signatures may prove to be novel cancer biomarkers is
apparent from this study's preliminary finding that
unique sets of miRNAs are associated with breast cancers
currently defined by their ErbB2 status (let-7f, let-7g, miR-
107, mir-10b, miR-126, miR-154 and miR-195) or their ER/
PRstatus (miR-142-5p, miR-200a, miR-205 and miR-25).
Several of the breast cancer miRNAs identified in the
present microarray analysis [10b, 21, 34, 125a, 125b, 126
145] were also found to be deregulated in a recent miRNA
survey of a phenotypically more diverse breast cancer
panel [14].
In sum, the present study has demonstrated the feasibility
and utility of measuring miRNA profiles from clinically
relevant biopsy samples using an optimized high-
throughput microarray assay platform. Application of this
methodology to the analysis of prostate and breast cancer
biopsy samples suggests that specific miRNA expression
signatures may be identified which, upon further evalua-
tion, may prove to have important diagnostic, prognostic
or predictive clinical value as cancer biomarkers.
Methods
Cell lines, breast tissue samples, and isolation of miRNAs
Initial methods development utilized cancer cell lines that
were readily available in our lab. The prostate cancer cell
lines, PC3 and LNCaP, and the breast cancer cell line,
SKBr3, were grown at 37°C at 5% CO2 in RPMI-1640
media (Sigma) supplemented with 10% FBS and 100 U/
ml penicillin and 100 µg/ml streptomycin. RNA obtained
from these cancer cell lines was enriched for microRNAs
using the mirVana miRNA Isolation Kit from Ambion
(Austin, TX) according to manufacturer recommenda-
tions. Total RNA was Trizol (Invitrogen, Carlsbad, CA)
extracted from 20 cryobanked primary breast cancer biop-
sies (-80° C, Bari, Italy), clinically annotated only for
patient age (average 55 years, range 29–79 years), tumor
state (stage I or II), histology (invasive ductal, grade,
>50% malignant cellularity), ErbB2 (gene copy amplifica-
tion), ER/PR (nuclear protein overexpression) positivity,
proliferation index (Ki-67/MIB-1) and p53 mutation
(exon 5–8) status. Similarly, total RNA was Trizol
extracted from 15 cryobanked prostate core biopsy sam-
ples (UCSF Tissue Core) clinically annotated for patient
age (average 63 years, range 52–70), histology (tumor
grade, % malignant cellularity), and PSA. Control tissue
used for comparison against the breast cancer samples
was commercially obtained (Ambion, Austin, TX) and
consisted of histologically normal breast tissue resected
from a 55 year old woman; the commercially obtained
(Ambion) control tissue used for comparison against the
prostate cancer samples consisted of histologically normal
prostate tissue resected from a 79 year old male. MicroR-
NAs were isolated from 500 ng total RNA extracted from
normal or malignant breast tissues and from ≤100 ng total
RNA extracted from the prostate biopsies, using the mir-
Vana miRNA Isolation kit with their modified protocol
for isolation of small RNAs. All microRNA measurements
and unsupervised hierarchical clustering analyses were
performed blinded to all annotated clinical features.
Microarray methods
Printing, post-processing, and analysis of the microarrays
was performed as described [36]. An oligonucleotide
microarray was constructed containing all of the anno-
tated human microRNA genes in the miRNA Registry [37].
Oligonucleotide probes identical to the sense orientation
of the mature human miRNA sequences were synthesized
by Operon Biotechnologies (Huntsville, AL) and dupli-
cate spotted in 3X SSC on Gold Seal microslides (Becton
Dickinson, Bedford, MA) coated with poly-l-lysine using
a linear servo arrayer at the UCSF Core Facility for Genom-
ics and Proteomics. Arrays were printed with probes con-
sisting of a tandem repeat or dimer of the mature
sequences (Additional file 6). In regard to oligonucleotide
probe design for microarrays, others have demonstrated
that increased sensitivity for microarray profiling can be
gained by spotting probes that consist of multimers of the
mature miRNA sequences [38]. At the time of printing the
arrays contained all of the annotated human microRNA
genes in the miRNA Registry as of November, 2004
(approximately 200). Some experiments used to validate
the amplification method were performed using anti-
sense arrays spotted and hybridized as previously
described [38]. Data were submitted to the GEO database
(accession numbers GSE4572, GSE4574 and GSE4589).
Amplification, labeling and hybridization of microRNAs
MicroRNAs were amplified using the SenseAmp Plus
amplification protocol [39] for miRNA from Genisphere
(Hatfield, PA). The amplification procedure produces a
"sense" copy of the RNA with short poly A sequences onMolecular Cancer 2006, 5:24 http://www.molecular-cancer.com/content/5/1/24
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both the 3' and 5' ends. Amplifications were performed
with as little as 250 pg of enriched miRNA (~2 ng total
RNA). For amplification input titration experiments five
different amounts of miRNA (0.5–27.0 ng) were used.
The resulting sense RNAs were quantitated using the Ribo
Green RNA Quantitation kit from Molecular Probes
(Eugene, OR). Unamplified samples enriched for miRNA
and amplified miRNA samples were labeled with the
Array900 miRNA kits from Genisphere according to the
manufacturer protocol (Additional file 1). Briefly, 10–200
ng of enriched miRNA was used in the initial tailing reac-
tion using E. coli Poly A Polymerase. The tailed miRNA
was reverse transcribed using an oligo dT primer that
incorporates a capture sequence tag on the miRNA. Two
tagging sequences/primers were used in these experi-
ments, one for binding to Cy3 labeled dendrimers [5'-
TTCTCGTGTTCCGTTTGTACTCTAAGGT GGA-T(17)-3']
and a second for binding Cy5 labeled dendrimers [5'-ATT-
GCCTTGTAAGC GATGTGATTCTATTGGA-T(17)-3']. A
hybridization mix containing the Cy3 and Cy5 tagged
miRNA was hybridized to the array under a glass cover
slip at 46°C for 16 hours in a Hybex hybridization oven
(SciGene, Sunnyvale, CA). After washing the arrays a sec-
ond hybridization using Cy3 and Cy5 labeled dendrimers
having complementary sequences to the tags was run for
4 hours at 60°C to generate the fluorescent signal. Specific
conditions used in amplification and labeling experi-
ments are described in further detail in the Results section.
Quantitative RT-PCR measurement of microRNAs
MicroRNA expression was also measured using a pre-
release version of the TaqMan miRNA quantitative PCR
assay from Applied Biosystems (Foster City, CA) that has
been previously described [25]. Expression levels of all the
annotated human miRs as of September, 2004 were ana-
lyzed using real-time TaqMan RT-PCR with the ABI PRISM
7900 instrument (Applied Biosystems, Foster City, CA).
Briefly, cDNA was made from enriched miRNA in 15-µL
reactions (1 ng/µl final concentration) using (Multiscribe)
MuLV reverse transcriptase and specific primers for each
miRNA. The cycle parameters for the RT reaction are 16°C
for 30 minutes, 42°C for 30 minutes, 85°C for 5 minutes,
hold at 4°C. The PCR reaction mix consists of the RT
product, Taqman 2X Universal PCR Master Mix and the
appropriate 5X MicroRNA Assay Mix containing primers
and probe for the miRNA of interest. Cycle parameters for
the PCR reaction are 95°C for 10 minutes (AmpliTaq
Gold enzyme activation), followed by 40 cycles of a dena-
turing step at 95°C for 15 seconds and an annealing/
extension step at 60°C for 60 seconds. All reactions were
run in triplicate. Due to the fact that the samples used for
these experiments were enriched for microRNA, it was not
possible to normalize expression to the typical house-
keeping genes as is done for mRNA expression. Previous
experiments during development of the microRNA Taq-
Man assays demonstrated that let-7 and miR-16 share
similar and highly abundant expression between various
cell lines (see Additional file 7 for expression in PC3 and
LNCaP cells). The expression of each miRNA relative to
let-7 and miR-16 was determined using the ∆∆Ct method.
The threshold cycle (Ct) is defined as the fractional cycle
number at which the fluorescence passes the fixed thresh-
old. For our experiments four replicates each of LNCaP
and PC3 were run in triplicate, two of which were normal-
ized to miR-16 and the other two were normalized to let-
7. Average fold differences were calculated by normalizing
the relative expression (∆∆Ct values) in the LNCaP cell
line to that in the PC3 cell line. Average fold differences
below 0.5 or above 2.0 were considered to represent a sig-
nificant difference between the two cell lines.
Bioinformatic and statistical analyses
Cy3 and Cy5 median pixel intensity values obtained using
Genepix 3.0 software (Axon, Foster City, CA) were back-
ground subtracted, and Cy3/Cy5 ratios were obtained.
Cy3/Cy5 ratios were log-transformed (base 2) and hierar-
chically clustered (average linkage correlation metric)
using the Cluster program from Stanford University [40].
Database calculations were performed and expression
maps were generated with SAM (Significance Analysis of
Microarrays) for Excel [41]. The Cy3/Cy5 ratios were com-
pared between the PC3 and LNCaP cells in SAM using a
one class analysis, with a two class analysis used for com-
parison of normal and malignant tissue samples. For the
comparison of the RT-PCR data to the array results, the
average fold differences for each gene were log-trans-
formed (base 2) and compared to the similarly log-trans-
formed (base 2) Cy3/Cy5 ratios obtained after Cluster and
SAM analysis. Inter-sample comparison of the prostate
and breast tumor miRNA profiles were visualized with
Cluster and Java TreeView [42]. Genepix median of ratio
values from experiments were log-transformed (base 2)
and filtered for genes where data were present in 80% of
experiments. Genes and arrays were hierarchically clus-
tered, as described earlier, and miRNA expression heat
maps were generated using SAM. The breast cancer
miRNA heat map generated by unsupervised clustering
analysis was subsequently labeled according to each can-
cer sample's clinical annotation for ErbB2 (+, -), ER (+, -),
and PR (+, -) status. Fisher's Exact (2 × 2, 2 × 3) tests were
performed to test the ability of the 2 and 3 most promi-
nent dendrogram arms identified by unsupervised cluster-
ing to classify the set of breast cancer samples in
accordance with their clinical annotation.
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